Impact Factor
3.47
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
3.71
323 total citations
h5-index
25
h5 depth signal
Cited share
79.3%
73 of 92
Total citations
323
Citation footprint
Metric signal
3.58
External metric anchor
Self-citation
0.3%
1 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
141
China
131
Italy
102
United Kingdom
81
Germany
42
Citing Fields of Research
Allergies
278
Respiratory Support
170
Lung Cancer
83
Immunology
77
Auto-Inflammatory Disorders
71
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
2,250
Articles tracked across the journal lifetime
Indexed publication set
92
73 cited publications
Last 12 months
30
2.7 publications/month
Open access share
16.7%
5 OA publications in the last year
Leading citing country
United States
141 citing publications
Leading citing field
Allergies
278 citing publications
Latest tracked publication
17 October 2026
10 recent records available
Coverage & Indexing History
v10n1, 1997-
v10n1, 1997-
Active Coverage
Research Focus & Classification
Indexed Subjects
Allergies
Lung Cancer
Respiratory Support
Cystic Fibrosis
Auto-Inflammatory Disorders
Immunology
Broad Categories
Pharmacology
Pulmonary Medicine
Allergies
Cystic Fibrosis
Auto-Inflammatory Disorders
Respiratory Support
Cardiology
Cancer, Autophagy & Apoptosis
MeSH Descriptors
Lung Diseases
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1016/j.pupt.2026.102456
Open DOI
Pharmacological Enhancement of O-GlcNAcylation Attenuates Lung Ischemia-Reperfusion Injury
02
03
DOI 10.1016/j.pupt.2026.102452
Open DOI
Belumosudil improves experimental pulmonary fibrosis via the ROCK2/Smad3/CTGF pathway
04
DOI 10.1016/j.pupt.2026.102451
Open DOI
Steroid-sparing strategies in respiratory diseases: efficacy and safety of current therapeutic options
05
06
07
DOI 10.1016/s1094-5539(26)00038-6
Open DOI
Editorial Board
08
09
DOI 10.1016/j.pupt.2026.102439
Open DOI
Methodological considerations on the effectiveness of biologics in asthma-COPD overlap
10
DOI 10.1016/j.pupt.2026.102438
Open DOI
m6A reader IGF2BP2 mediates airway remodeling by stabilizing Dixdc1 in asthma pathogenesis
Bibliographical & Catalog Notes
Title from cover.
Available also online.